Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double immune attack: new cell combo targets tough childhood cancers

NCT ID NCT07211737

Not yet recruiting Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This early-phase study tests a new combination of two different immune cells—NK cells and CAR-T cells—for children and young adults with neuroblastoma or osteosarcoma that has returned or not responded to standard treatments. The NK cells are designed to help the CAR-T cells work better in the tumor environment. The main goals are to find the safest dose and see if the treatment can shrink tumors. About 27 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY NEUROBLASTOMA REFRACTORY OSTEOSARCOMA RELAPSED NEUROBLASTOMA RELAPSED OSTEOSARCOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••